Phase 2 Melanoma Trial, Recruiting NCT06214156 Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Condition: Melanoma
Back to Melanoma

Phase 2 Melanoma Trial, Recruiting

NCT06214156
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with advanced melanoma
  • People who have at least one tumour that can be measured on a scan
  • People whose general health and ability to carry out daily activities is rated as good or mostly independent (ECOG score of 0 or 1)
  • People whose doctors expect them to live for more than 12 weeks
  • People whose blood and other lab test results meet the trial's required levels (confirm with trial site for specific values)
  • Women who could become pregnant must have a negative pregnancy test within 7 days before the first dose, and must use effective contraception from signing the consent form until at least 6 months after the last dose
  • Men who could father a child must use effective contraception from signing the consent form until at least 6 months after the last dose, and must agree not to donate sperm during that time
  • People who understand the trial, are willing to sign the consent form, and are able to follow all trial requirements

Who may not be able to join:

  • People who have received other cancer treatments within a certain period before the trial starts (confirm with trial site for specific timeframe)
  • People who have had another type of cancer within a certain period before the trial starts (confirm with trial site for specific timeframe)
  • People who have a history of, or currently have, serious heart or blood vessel conditions
  • People who currently have an ongoing infection that requires treatment through a drip (intravenous antibiotics or antiviral medication)
  • People who have an autoimmune disease, or have had one in the past (where the immune system attacks the body's own tissues)
  • People who have a known mental health condition that might make it difficult to follow the trial's requirements
  • People who have a build-up of fluid around the lungs, heart, or abdomen that needs to be drained, or who had such drainage within a set period before joining the trial (confirm with trial site for specific timeframe)
  • People who need ongoing treatment with anti-herpes virus (anti-HSV) medication during the trial period
  • People who have received a live or weakened (attenuated) vaccine within a certain period before the trial starts, plan to receive one during the trial, or have ever received any cancer vaccine in the past
  • People who had major surgery within a set period before the trial starts and have not fully recovered, or who plan to have major surgery during the trial (confirm with trial site for specific timeframe)
  • People who have had a history of drug use, drug abuse, or alcohol abuse in the year before signing the consent form
  • Women who are pregnant, breastfeeding, or planning to become pregnant or have children during the trial
  • People whose doctor leading the trial considers them unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0086-010-88196370

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Registry
ClinicalTrials.gov
Start date
26 January 2024
Est. completion
30 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Treatment-Emergent Adverse Events; Objective response rate(ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov